Tandem Diabetes Care (TNDM) PT Lowered to $51 at Barclays
Tweet Send to a Friend
Barclays analyst Matt Miksic lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $51.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
